Bayer AG
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BAYRY research report →
Companywww.bayer.com
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy.
- CEO
- William N. Anderson
- IPO
- 1996
- Employees
- 90,587
- HQ
- Leverkusen, DE
Price Chart
Valuation
- Market Cap
- $44.60B
- P/E
- -17.88
- P/S
- 0.85
- P/B
- 1.34
- EV/EBITDA
- 7.30
- Div Yield
- 0.28%
Profitability
- Gross Margin
- 59.32%
- Op Margin
- 15.38%
- Net Margin
- -4.77%
- ROE
- -7.52%
- ROIC
- 8.42%
Growth & Income
- Revenue
- $43.78B · -6.07%
- Net Income
- $-3,477,128,000 · -36.25%
- EPS
- $-0.88 · -36.15%
- Op Income
- $6.68B
- FCF YoY
- -56.39%
Performance & Tape
- 52W High
- $14.85
- 52W Low
- $6.69
- 50D MA
- $11.27
- 200D MA
- $10.10
- Beta
- 0.84
- Avg Volume
- 1.29M
Get TickerSpark's AI analysis on BAYRY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BAYRY Coverage
We haven't published any research on BAYRY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BAYRY Report →